Firebrick Pharma Issues Over 21.6 Million New Shares and Confirms Regulatory Compliance

The latest update is out from Firebrick Pharma Limited ( (AU:FRE) ).

Firebrick Pharma has issued 21,636,603 new ordinary fully paid shares, comprising 21,276,603 shares from a recent placement at $0.047 each and 360,000 shares from the exercise of options at $0.0217. The company confirmed the shares were issued without a prospectus under applicable Corporations Act provisions and stated it remains compliant with continuous disclosure and financial reporting obligations, with no excluded information relevant to assessing its financial position or the rights attached to the new securities.

The share issue strengthens Firebrick Pharma’s capital base as it advances the commercial rollout of its povidone-iodine–based Nasodine product range in existing and new markets. By affirming regulatory compliance and the absence of undisclosed material information, the company seeks to provide assurance to investors about governance standards and the transparency of its capital-raising activities.

More about Firebrick Pharma Limited

Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine. Its lead product, Nasodine Nasal Spray, has been launched in the United States, Singapore, and Fiji & South Pacific, with further market approvals being pursued, while a follow-on Nasodine Throat Spray is available in Singapore and Fiji.

Average Trading Volume: 89,392

Technical Sentiment Signal: Sell

Current Market Cap: A$14.39M

For an in-depth examination of FRE stock, go to TipRanks’ Overview page.